Skip to Content Skip to Content
  • Campus & Community
  • Four from Penn named 2025 Sloan Research Fellows

    Jason Altschuler, César de la Fuente, Liang Wu, and Anderson Ye Zhang have been honored as early-career researchers and scholars for their accomplishments, creativity, and potential to become leaders in their fields.
    Four portraits arranged in a 2x2 grid. Clockwise from top left: Jason Altschuler, Cesar de la Fuente, Liang Wu, and Anderson Ye Zhang
    Jason Altschuler (top left) and Anderson Ye Zhang (bottom left) of the Wharton School, Liang Wu (bottom right) of the School of Arts & Sciences, and César de la Fuente (top right) of the Perelman School of Medicine have been named 2025 Sloan Research Fellows. They are among 126 early-career scientists in North America chosen this year to receive the two-year, $75,000 fellowship in recognition of their accomplishments, creativity, and potential to become leaders in their fields.

    Recent Articles

  • More Articles
  • The Fed explained: What it does and why it matters
    Photo of the Federal Reserve facade

    (Image: Lance Nelson)

    The Fed explained: What it does and why it matters

    Former Philadelphia Fed President Patrick Harker and financial historian Peter Conti-Brown, both Wharton professors, unpack the central bank’s origins, its unusual structure, and the quiet ways it shapes the economy

    May 13, 2026

    Fighting oral cancer with bioengineered chewing gum
    A latex-gloved hand hoding a petri dish of medical chewing gum.

    A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.

    (Image: Kevin Monko/Penn Dental Medicine)

    Fighting oral cancer with bioengineered chewing gum

    Research led by Penn Dental’s Henry Daniell shows that antiviral and antibacterial chewing gums reduce the levels of three microbes linked to worse outcomes in oral cancers, paving the way for more effective and affordable therapies.

    Apr 20, 2026